Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 330 versus TERCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 330 versus TERCONAZOLE.
FULVICIN P/G 330 vs TERCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Terconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and function.
330 mg orally once daily with fatty meal to enhance absorption.
Intravaginal cream (0.4%, 0.8%): one applicatorful (approximately 5 g) intravaginally once daily at bedtime for 7 days; vaginal suppository (80 mg): one suppository intravaginally once daily at bedtime for 3 days.
None Documented
None Documented
Clinical Note
moderateTerconazole + Tranilast
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tranilast."
Clinical Note
moderateTerconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tolfenamic acid."
Clinical Note
moderateTerconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Terconazole is combined with Nimesulide."
Clinical Note
moderateTerconazole + Risedronic acid
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
Terminal elimination half-life is approximately 25-37 hours, allowing once-daily dosing for vaginal infections.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Primarily hepatic metabolism with biliary excretion; approximately 60-80% of the dose is excreted in feces as metabolites, and about 20% in urine mostly as inactive metabolites.
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Terconazole is combined with Risedronic acid."